Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Last year

Un­rav­el­ing the Com­plex­i­ties of Can­cer through More Hu­man-rel­e­vant Mod­els

Last year

Clin­i­cal Stud­ies In Japan To­day: An­oth­er Look At The World’s Sec­ond-Largest Pre­scrip­tion Drug Mar­ket In A Post-Pan­dem­ic World

Last year

Con­nec­tiv­i­ty in mo­tion: The art and sci­ence of cre­at­ing ex­pe­ri­ences that in­form and in­spire health­care pro­fes­sion­als

Last year

The Rare Kid­ney Dis­ease Play­book: How New Re­search and In­no­va­tion is Trans­form­ing the RKD Treat­ment Land­scape

Last year

Can Biotech In­no­va­tion With­stand Dis­rup­tion?

Last year

Re­think­ing Treat­ments for GAD: Progress in Sight for Pa­tients in Need

Last year

Ex­plor­ing new fron­tiers in rare dis­ease re­search to meet the needs of pa­tients

Last year

A Wind­ing Road Ahead for Biotech?

Last year

I'll be in Lon­don next week with the End­points crew and a great line­up of biotech ex­perts and in­sid­ers. Join us

Last year

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal mar­ket

Last year

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

Last year

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Last year

Ad­vanc­ing Sleep Med­i­cine: Pi­o­neer­ing Re­search and Car­dio­vas­cu­lar Health in Nar­colep­sy

Last year

In­no­va­tion and growth: key in­gre­di­ents for health­care M&A

Last year

How Clover­tex blends be­spoke and off-the-rack cloud com­put­ing in Phar­ma

Last year

The RIGHT pro­tein and the case for cryo-EM with Pro­teros

Last year

PRO­TAC® Pro­tein De­graders: How Arv­inas is Pi­o­neer­ing Po­ten­tial Next-Gen­er­a­tion Treat­ments for Neu­rode­gen­er­a­tive Dis­eases

Last year

A Look In­side the Bou­tique En­roll­ment Agency Spon­sors Are Clam­or­ing to Work With

Last year

How to Ac­cel­er­ate De­vel­op­ment in Nov­el & Ad­vanced On­col­o­gy Ther­a­pies - From the Start­ing Line

Last year

Save Time and Up to 43.5% on Clin­i­cal Tri­al Spend Con­duct­ing Aus­tralian and US Tri­als

Last year

Im­muno-On­col­o­gy 2.0: How Re­gen­eron is Uti­liz­ing its Ex­per­tise in An­ti­bod­ies to Lead the Next Wave of Com­bi­na­to­r­i­al Ap­proach­es in Can­cer Care

Last year

No Good Drug Left Be­hind: Sen­si­tiv­i­ty and Speci­fici­ty in Drug De­vel­op­ment Ex­plained

Last year

The Path to Pro­duc­tiv­i­ty: Tack­ling the Cri­sis in Drug De­vel­op­ment us­ing Im­proved Pre­clin­i­cal Mod­els

Last year
First page Previous page 123456 Next page Last page
A service from the Financial Times